heparine injection bp 5,000 units/ml solution for injection
rotexmedica gmbh arzneimittelwerk bunsenstrasse 4, 22946 trittau, germany - heparine sodium - solution for injection - 5,000 units heparine sodium per ml - antithrombotic agents: heparin group
cal-heparine 20000 i.u./0.8ml amp.
amoun pharmaceutical industries co. - injection - 20000 i.u.
cal-heparine 12000i.u.amp.
amoun pharmaceutical industries co. - injection - 12000 i.u.
cal-heparine 5000i.u. amp.
amoun pharmaceutical industries co. - injection - 5000 i.u.
heparine iu 5ml inj
biological e. - heparin - inj - 1000iu/ml - 5ml
heparine iu 5ml inj
biological e. - heparin - inj - 5000iu/ml - 5ml
heparine leo 5000 iu/ml inj./inf. sol. i.v. vial
leo pharma sa-nv - heparin sodium 5000 iu/ml - solution for injection/infusion - 5000 iu/ml - heparin sodium 5000 iu/ml - heparin
heparine leo 100 iu/ml inj. sol. i.v. vial
leo pharma sa-nv - heparin sodium 100 iu/ml - solution for injection - 100 iu/ml - heparin sodium 100 iu/ml - heparin
heparine natrium b. braun 25000 iu/5 ml inj. sol. i.v. vial
b. braun melsungen ag - heparin sodium 25000 iu/5 ml - solution for injection - 25000 iu/5 ml - heparin sodium 25000 iu - heparin
thorinane
pharmathen s.a. - enoxaparin sodium - venous thromboembolism - antithrombotic agents - thorinane is indicated for adults for: - prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery. - prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 ml). - treatment of deep vein thrombosis (dvt), complicated or uncomplicated by pulmonary embolism. - treatment of unstable angina and non q wave myocardial infarction, in combination with acetylsalicylic acid (asa). - treatment of acute st segment elevation myocardial infarction (stemi) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 ml, 80 mg/0.8 ml, and 100 mg/1 ml). - blood clot prevention in the extracorporeal circulation during haemodialysis. prevention and treatment of various disorders related to blood clots in adults.,